NEW YORK ( TheStreet) -- Stay here all day for live coverage from the second and final day of the BIO CEO & Investor Conference.

The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks.

Pfizer's ( PFE - Get Report) Dr. Mikael Dolsten, Head of Worldwide Research, kicks off the BIO conference this morning with a breakfast "fireside chat" at 8 am ET.

Around the same time, Idenix Pharmaceuticals ( IDIX), CEO Ron Renaud will be speaking on CNBC. Given that he's pre-booked for the network likely means he won't be announcing the takeout deal investors have been pining for, but his comments on future plans for his company's hepatitis C drugs will be closely followed. Renaud presents at the BIO conference later this morning.

Other noteworthy presenting companies Tuesday include Delcath Systems ( DCTH), Keryx Pharmaceuticals ( KERX), Oncothyreon ( ONTY), Acorda Therapeutics ( ACOR - Get Report) and Human Genome Sciences ( HGSI).

Gilead Sciences' ( GILD - Get Report) President John Milligan will also be featured in a "fireside chat" this afternoon.

I have one-on-one meetings today with Acorda, BioMarin Pharmaceuticals ( BMRN - Get Report) and Affymax ( AFFY)

To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag.

An archive of tweets and comments from Day One of the BIO CEO conference is still available.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.